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RESUME 
L'hyperhémie réactive, définie comme l'augmentation transitoire du flux sanguin après 
une courte période d'ischémie, pourrait être influencée par des vasoconstricteurs de la 
famille des prostanoïdes, telle que la thromboxane. 
Le terutroban (S18886) est un antagoniste spécifique des récepteurs à la thromboxane. 
L'étude présentée a cherché à déterminer l'effet du terutroban sur l'hyperhémie réactive 
dans la peau et le muscle squelettique de l'avant-bras de volontaires sains. 
Vingt volontaires sains ont été randomisés en aveugle pour recevoir oralement 30mg/j 
de terutroban ou un placebo pendant 5 jours puis réciproquement pendant une 
deuxième période de 5 jours, selon un schéma cross-over. L'ischémie transitoire a été 
provoquée par l'occlusion de l'artère brachiale par une manchette gonflée au dessus de 
la pression systolique. L'hyperhémie réactive était évaluée dans les tissus de l'avant-
bras, en mesurant le flux sanguin, pour la peau par une méthode laser Doppler, et pour 
le muscle au moyen d'une pléthysmographie par jauge de contrainte durant une 
occlusion veineuse. 
Au premier et au dernier jour de chaque période de traitement, l'hyperhémie réactive 
était mesurée avant et 2 heures après l'ingestion du comprimé. 
Que ce soit dans la peau ou le muscle, le terutroban n'a pas montré d'effet sur le flux 
de pic post-occlusion ni sur la réponse globale d'hyperhémie, exprimée en aire sous la 
courbe. 
En conclusion, dans la peau et le muscle de sujets sains, l'hypérémie réactive n'est pas 
influencée par les récepteurs spécifiques à la thromboxane. 
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No Implication of Thromboxane Prostanoid Receptors in 
Reactive Hyperemia of Skin and Skeletal Muscle in 
Human Forearm 
Antoine Pasche, MD,* Abigael Heim, MD,* Lucas Liaudet, MD, t Bernard Waeber, MD,* 
and François Feihl, MD* 
Abstract: There is evidence that reactive hyperemia (ie, the transient 
increase of blood fiow above resting level after a short period of 
ischemia) could be negatively modulated by vasoconsttictor prostanoids. 
The present study tested whether pharmacological blockade of the 
thromboxane prostanoid receptors with the specific antagonist 518886 
(terntroban) would amplify reactive hyperemia in human skin and 
skeletal muscle. Twenty healthy young male volunteers were enrolled in 
a randomized, blinded, crossover tt·ial of oral 518886 30 mg/d for 5 days 
versus placebo. Reactive hyperemia was evaluated in foreann skin and 
skeletal muscle, after occlusion of the brachial arte1y with a pneumatic 
cuff infiated at suprasystolic pressure. Blood fiow was measured with 
laser Doppler imaging (skin) and stt11in gauge venous occlusion 
plethysmography (muscle). On the first and last day of each treatrnent 
period, recordings of reactive hyperemia were obtained immediately 
before and 2 hours after drng intake. Whether in forearm muscle or skin, 
518886 had no discernible effect on peak postocclusion blood fiow, nor 
on the global hyperemic response as quantified by the area under curve. 
These results do not support that thromboxane prostanoid receptor 
activation could exert a moderating influence on reactive hyperemia in 
human skin and skeletal muscle, at least in young subjects. 
Key Words: cyclooxygenase, thromboxane A2, reactive hyperemia 
(J Cardiovasc Pharmacof1M 2013;61:127-132) 
INTRODUCTION 
Reactive hyperemia (or synonymously postischemic 
vasodilation) refers to the transient vasodilation taking place 
in many tissues when perfusion is reestablished after a short 
interruption. In man, reactive hyperemia is relatively simple 
to evaluate in forearm muscle and skin, where reliable non-
invasive methods exist for the measurement of blood flow 
(respectively, strain-gauge plethysmography and laser Dopp-
ler flowmetry), whereas transient ischemia can be obtained 
easily by the inflation at suprasystolic pressure of a pneumatic 
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cuff placed on the upper arm. 1•2 Severa! studies have indicated 
that, recorded in this way, reactive hyperemia is linked to and 
thus could be used as a surrogate marker for cardiovascular 
risk.3- 11 However, one obstacle to such use might be the fact 
that many subjects at increased cardiovascular risk receive 
cyclooxygenase (COX) inhibitors, with a potential confounding 
influence on the measured vascular responses. 
COX catalyzes the transformation of arachidonic acid 
to prostaglandin H2, a common initial step that then leads, 
through multiple downstream pathways, to the formation of 
several biologically active compounds collectively termed 
prostanoids. There are essentially 2 isoforms of COX, COX-1, 
and COX-2, each coded by a different gene. Both can be 
found in a wide array of tissues, including the vascular 
endothelium and vascular smooth muscle. 12 Classically, the 
expression of COX-1 is constitutional, whereas COX-2 is 
induced by inflammation, but the presence ofCOX-2 has also 
been described in the absence ofinflammatory stimulus, nota-
bly in endothelial cells. 12 In humans, the development of 
hypertension seems associated with a shift in prostanoid pro-
duction from predominant control by COX-1 to predominant 
control by COX-2. 12 Prostanoids exert their biological effects by 
stimulating at least 5 different types ofreceptors, the IP, DP, EP, 
FP, and thromboxane prostanoid (TP). 13 Classically, the prosta-
noid PGI2 (prostacyclin) specifically ligates the IP receptor, lead-
ing in blood vessels to vasodilation and inhibition of coagulation, 
whereas thromboxane A2 (TxA2) stimulates the TP receptors, 
with the opposite consequences. The increased cardiovascular 
risk associated with the intake of some phannacological COX 
inhibitors, such as rofecoxib (selective for COX-2) or diclofenac 
(nonselective) has been explained by an induced shift in the 
balance of PGI2 and TxA2 in favor of the latter. 14•15 The phys-
iology and pathophysiology of prostanoids is rendered more 
complex by the fact that some of these compounds may ligate 
more than 1 receptor type, potentially leading to confiicting ef-
fects. A case in point is that of prostaglandin D2, which may 
stimulate both endothelial DP receptors (leading to endothelium-
dependent vasodilation) and vascular smooth muscle TP 
receptors ( endothelium-independent vasoconstriction). 12 
In view of this complexity, it is not surprising that, in 
healthy humans, the impact of COX inhibitors on the reactive 
hyperemia of skin9•1&-21 or forearm muscle21- 25 has been vaiiable, 
ranging from marked or modest blunting,21- 25 no effect,18•19 to 
marked potentiation.20 One potential reason for these discrepan-
cies might reside in differences between studies regarding the 
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relative impact of the administered drug on the production of 
vasoconstrictive versus vasodilator COX products. To examine 
this possibility, it would be necessary to selectively block the 
action of vasoconstrictor prostanoids. 
In hmnan forerann, a short transient ischemia (3-10 
minutes) is followed by an increased concentration in effluent 
venous blood of thromboxane B2, the stable metabolite of 
TxA2.26--29 Thus, in this vascular territory at least, the stimu-
lation of TP receptors might contribute to limit reactive 
hyperemia. In the present study, we hypothesized that admin-
istration to healthy volunteers of S 18886 (terutroban), a selec-
tive antagonist of TP receptors,30•31 would enhance reactive 
hyperemia in forearm skin and muscle. 
MATERIALS AND METHODS 
Subjects 
All participants were fully informed about the protocol of 
the study and gave their written consent. The study confonned 
to the principles outlined in the Declaration of Helsinki and was 
approved by the institutional review board and by the Swiss 
regulatory authorities (Swissmedic ). 
The study took place from April 5, 2007, to November 
21, 2007. Twenty white male healthy subjects, aged 18-30 
years, were enrolled. Inclusion criteria were an inconspicuous 
medical history without bleeding disorder, no remarkable 
findings on clinical examination, and normal results on the 
following laboratory tests: blood cell count, potassium, sodium, 
calcium, creatinine, total protein, glucose, liver, pancreatic, and 
coagulation (prothrombin time, partial prothromboplastin time, 
fibrinogen, and platelet function), platelet function assessed with 
the PFA-100 System (Siemens Healthcare, Erlangen, Germany). 
Additional requirements were negative serology for hepatitis B 
and C virus and HN, normal electrocardiogram, negative urine 
analysis for blood (dispstick), and drugs (minimal test). 
Exclusion criteria were a planned strenuous activity 
during the study period, surgery in the 3 months before the 
study or planned during the study, excessive use of alcohol 
(>45 g/d), excessive intake of caffeine beverage (~5 cups/ 
d or ~500 mg of caffeine/d), use of any addictive substance, 
regular use of agents suppressing gastric acidity, and use any 
drugs affecting hemostasis in the 10 days preceding inclusion 
(anticoagulant agents, antiplatelet drugs, steroidal and nonste-
roidal anti-inflammatory drugs, and drug containing salicylates). 
Assessment of Reactive Hyperemia 
Reactive hyperemia was elicited in the forearm by 
temporarily occluding the ipsilateral brachial artery with 
a standard size pneumatic cuff placed around the upper ann 
and inflated above systolic pressure (200 mm Hg). For skin 
assessment, occlusion times of3 minutes and then 30 seconds 
were used, with 5 minutes of reperfusion allowed in between. 
For muscle assessment, the occlusion time was 5 minutes. 
Separate maneuveurs were carried out on the dominant side 
and the nondominant side for the recording of reactive 
hyperemia in forearm muscle and forearm skin, respectively. 
Foreann muscle blood flow was assessed using venous 
occlusion strain-gauge plethysmography (Hokanson, Bellevue, 
W A), with the hand excluded by means of an pneumatic cuff 
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inflated around the wrist, as described previously.21 Skin blood 
flow was measured on the volar face of the forearm, using a 
laser Doppler imager (LDI; Moor Instruments, Axminster, 
United Kingdom), as described previously. 2•21 
Study Design and Protocol 
The study was single center, placebo controlled, cross-
over, and triple blinded (participants, investigators, and data 
collector). For each participant, the sequence of treatment 
(active drug first or placebo first) was randomly assigned at 
inclusion. To ensure that the treatrnent was given blindly after 
randomization, tablets ofidentical appearance containing either 
placebo or the active drug were prepared by the Institut de 
Recherches internationales Servier (Courbevoie, France) and 
sent to our center. The active drug was the TxA2 receptor 
blocker S 18886 (terutroban), 30 milligrams per tablet. 
The complete protocol comprised 1 selection and 4 inves-
tigation sessions. The various eligibility and exclusion criteria 
were checked on the selection session and rechecked 7 days later 
on investigation session 1 (Fig. lA). Randomization took place 
on investigation session 1. The first treatrnent period lasted from 
investigation session 1 to investigation session 2, 5 days later. A 
washout period of 10-15 days followed. The second treatrnent 
period then started on investigation session 3 and lasted 5 
additional days, until investigation session 4. A single tablet 
containing Sl8886 30 mg or placebo was administered on 
each day of each treatment period, at 8:00 AM. 
Investigation 
Session 1 
Randomisation Investigation 
Investigation 
Session 3 Investigation 
Session 4 1 Session 2 
Selection t 
Session ! 
A 
i 818886 30 mg/day 
7 days Placebo 
Period 1 
5 days 
Investigation 
Session 1 or 3 
,..-----"-, 
Hy21 
'
Hy11 1, 
,,,. * 
Washout 
10-15 days 
818886 30 mg/j 
Period 2 
5 days 
Investigation 
Session 2 or 4 
,..-----"-, 
Hy41 
Hy3! i 
, 11, 
B Day1 Day2 Day3 Day4 Day5 
FIGURE 1. Study design. A, Crossover design, see text for 
explanations. B, Details of 5-~ay study period. T~i~k gr~y arrows 
designate oral intake of a single tablet contammg e1ther the 
active drug (Sl 8886) or placebo. Stippled arrows labeled Hyl 
to Hy4 designate recordings of reactive hyperemia in forearm 
muscle and skin. Hyl carried out immediately before and Hy2 2 
hours after intake of first tablet. Hy3 and Hy4 similarly bracket 
intake of the fifth tablet. 
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TABLE 1. Characteristics of Study Subjects 
No. Subjects 
Age, yrs 
Weight, kg 
Height, cm 
BMI, kg/m2 
Body temperature, °C 
Heart rate, beats/min 
Blood pressure, mm Hg 
Systolic 
Diastolic 
Data are mean and SD. 
BMI, body mass index. 
20 
24.4 ± 2.5 
75.4 ± 8.1 
181 ± 5 
23 ± 2.3 
36.5 ± 0.3 
63 ± 12 
124 ±Il 
68 ± 13 
To guarantee treatment compliance, the subjects had to 
report daily to the laboratory in the early morning, so that one 
investigator could hand over the appropriate tablet and verify 
its actual ingestion. 
Starting from the selection session and for the entire 
duration of study, the subjects were instructed to avoid all the 
following: use any drugs affecting hemostasis (anticoagulant 
agents, antiplatelet drugs, steroidal and nonsteroidal anti-
inftammatory drugs, and drug containing salicylates), use of 
any addictive substance, and use of agents suppressing gash·ic 
acidity. An additional requirement was to avoid any intake of 
caffeine beverage in the 24 hours preceding each session. 
On each investigation session, reactive hyperemia in 
skin and muscle was examined immediately before and 2 
hours after drug intake. In Figure lB, these examinations are 
designated as Hyl (beginning of treatment period, immedi-
ately before intake of the first tablet), Hy2 (2 hours after 
intake of :first tablet), Hy3 (fifth day of treatment period, 
immediately before intake of the fifth tablet), and Hy4 
(2 hours after intake offifth tablet). The timing ofHy2 relative 
to Hyl and Hy4 relative to Hy3 was based on the known 
pharmacodynamies of Sl8886. A single oral 30 mg dose of 
this drug affects maximal inhibition of platelet aggregation, 
starting after 30 minutes and maintained for at least 12 
hours.30,31 
· All investigations took place in a quiet room with air 
conditioning. Ambient temperature was kept between 21°C 
and 23.5°C. The subjects were examined in the supine posi-
tion with arms supported by a cushion. On each vascular 
investigation, each type of reactive hyperemia (forearm mus-
cle and foreann skin) was determined in triplicate, allowing 
10 minutes between deftation of the ann cuff used for arterial 
occlusion and its next inflation. Detenninations in foreann 
muscle were carried out first, on the dominant arm, and were 
followed by those in forearm skin, on the contralateral side. 
Data Analysis 
The recorded hyperemic response was summarized as 
(1) the baseline blood ftow (ie, immediately before arterial 
occlusion), (2) the peak blood ftow observed after release of 
aiierial occlusion and (3) the area under curve, as previously 
described.21 Statistical analysis was carried out with mixed 
model analysis of variance, using treatment (placebo or 
© 2013 Lippincott Williams & Willdns 
Baseline flow 
(ml blood/min/100g tissue) D Placebo 
Ill S18886 4 
3 
2 
0 
40 
20 
0 
30 
20 
10 
0 
Peak flow 
(ml blood/min/100g tissue) 
AUC 
(ml blood/100g tissue) 
Hy1 Hy2 Hy3 Hy4 
Treatment 
FIGURE 2. Reactive hyperemia in forearm muscle. Forearm 
blood flow measured with hand excluded, using venous occlu-
sion strain gauge plethysmography. Blood flow interrupted for 
5 minutes by pressurization at 200 mm Hg of a pneumatic cuff 
placed around the upper arm. Baseline flow measured immedi-
ately before cuff inflation. Peak flow maximal flow immediately 
after cuff deflation. AUC area under curve. Each subject went 
through two 5-day treatment periods. Treatment consisted in the 
daily ingestion of a single tablet containing 30 mg Sl 8886 in one 
period and placebo in the other. Timing of measurements: Hyl 
and Hy2 immediately before and 2 hours after intake of first tablet 
on first treatment day. Hy3 and Hy4 immediately before and 2 
hours after intake of fifth tablet on fifth treatment day. * p < 0.05, 
** p < 0.01 Hy2-Hy4 vs Hyl. None of the differences between 
treatments reached statistical significance. Data a means and SD, 
n = 20 subjects. 
S18886), examination number (Hyl-Hy4), and their interac-
tions as fixed factors repeated within subjects and subjects as 
random factors. The alpha level of all tests was set at 0.05. 
Data are summarized as mean and SD. All calculations were 
carried out with version 5 of the JMP software (SAS Institute, 
Cary, NC). 
RESULTS 
The demographic and hemodynamic characteristics of 
the remaining 20 subjects are shown in Table 1. Variables 
derived from reactive hyperemia in forearm muscle are 
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D Placebo 
1111 518886 
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FIGURE 3. Reactive hyperemia in forearm skin. Skin blood 
flow measured on volar face of forearm. Blood flow inter-
rupted for 3 minutes by pressurization at 200 mm Hg of 
a pneumatic cuff placed around the upper arm. See also leg-
end for Figure 2. None of the differences between treatments 
reached statistical significance. 
displayed in Figure 2. Identical results were obtained on the 
first examination of each treatment sequence (Hyl ), irrespec-
tive of whether placebo or active drng was subsequently 
received. In both treatment sequences, a slight but statistically 
significant increase in baseline flow (P = 0.016) and area 
under curve (P = 0.02), but not peak flow, was noted 2 hours 
after ingestion of the first tablet (Hy2 vs. Hy 1 ). A similar albeit 
not statistically significant trend occurred on the last day of each 
treatment sequence (ie, Hy4 vs. Hy2). The difference in baseline 
flow between Hy4 and Hy 1 was statistically significant (P = 
0.029). Most importantly, when compared with placebo, active 
treatment had no discernible effect on forearm muscle reactive 
hyperemia, at any tune point (Hy2, Hy3, and Hy4). 
The results regarding reactive hyperemia in forearm skin 
were essentially superilnposable with those in foreann muscle, 
except for the absence of time-dependent effects. Again, there 
was no detectable influence of Sl8886, whether reactive 
hyperemia followed a 3-minute occlusion (Fig. 3) or 30-second 
occlusion (data not shown). 
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DISCUSSION 
W e present here the first study assessing the impact of 
TP receptor blockade on reactive hyperemia. Our results do 
not support any major modulation by TP receptor activation 
of the reactive hyperemia triggered by shmt periods of ischemia 
in the foreann skin and skeletal muscle microcirculation of 
young healthy humans. 
In humans, several authors have explored the potential 
mediation of reactive hyperemia by vasoactive prostanoids, 
using the same investigation methods as in the present work 
and inhibition of COX with nonsteroidal anti-inflammatmy 
agents (AINS) as pharmacological tools. As mentioned in the 
Introduction, and displayed more accurately in Table 2, results 
have been variable and at tune inconsistent. When present at 
ail, the observed effects of AINS administered systemically 
were toward a reduced amplitude and/or duration of postis-
chemic vasodilation in muscle and skin. In contrast with these 
observations stands the study by Medow et al,20 who used 
microdialysis to locally expose the calf skin of healthy volun-
teers to the AINS ketorolac and as a result observed a 2-fold 
amplification of reactive hyperemia. Because of the large con-
centration of ketorolac perfused into the microdialysis catheter 
(10 mM), these authors probably achieved higher tissue drng 
levels and thus more complete COX inhibition than was pos-
sible with systemic administration. The heterogeneity ofresults 
shown in Table 1 might thus be explained by differences 
between studies in the degree of COX inhibition, leading to 
different impacts on the balance of vasodilator and vasocon-
strictor prostanoids. If this hypothesis is correct, then the data 
by Medow et al20 would implicate vasoconstrictor prostanoids 
as major moderators ofreactive hyperemia, at least in the skin. 
TxA2 is a major vasoconstrictor product of the COX 
pathway and, as reviewed in the Introduction, its production 
in human foreann appears stimulated by periods of ischemia as 
short (3-10 minutes) as carried out in the present study (skin 
3 minutes, muscle 5 minutes). In these vascular beds, there-
fore, we anticipated that antagonizing the binding of TxA2 to 
its specific TP receptor with Sl8886 would enhance postische-
mic vasodilation. This hypothesis was however not confirmed 
by our findings, which did not show any observable effect of 
Sl8886 onreactivehyperemia in the forearm (Figs. 2, 3), suggest-
ing a lack of influence ofTxA2 on this physiological process. 
One might argue that such a negative outcome might be 
related to an insufficient power of our study, due to the small size 
of the study population. However, a post hoc analysis carried out 
to verify this point indicated that, with the present design and 20 
subjects included, power was ;::::Q.8 to detect a ;::::JO% effect of 
treatment on either skin or muscle reactive hyperemia, had it 
been present on at least 1 of the 3 postdrng examinations. Thus, 
if our study missed an Îlnpact of Sl8886, as administered, on 
postischemic vasodilation, such impact is lilœly to be only minor. 
A second issue to be considered is that of dosage and 
bioavailability of the study drng. Drng intake took place in 
the systematic presence of the investigator, so that treatment 
compliance was not in doubt. Sl8886 was administered 
orally as a single dose of 30 milligrams per day for 5 days. 
Measurements at Hy2 and Hy4 took place 2 hours after drng 
intake, a timing chosen because it corresponds to the tüne to 
© 2013 Lippincott Williams & Wilkins 
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TABLE 2. Human Studies Concerning the Impact of COX lnhibitors on Reactive Hyperemia 
Reactive Inhibition of Observed Effects on Reactive 
Hyperemia COX Hyperemia 
Ischemic Route of 
Reference Tissue Time, min Agent Administration Dosage Peak Blood Flow AUC 
Kilbom and Muscle 5 Indomethacin 
Wennmalm22 
Rectal 1.25 mg/kg 25% decrease 50% decrease 
Carlsson et al24 Muscle 3 and 5 lbuprofen Oral 1200 mg 20%-25% decrease 60% decrease 
1, 10, and 20 Unchanged Unchanged 
Engelke et al25 Muscle 5 Ibuprofen Oral 1200 mg 20% decrease Unchanged 
Addor et al21 Muscle 5 Lysine Oral 1800 mg 15% decrease NA 
Skin 3 acetylsalicylate Unchanged NA 
Moppett et al18 Skin 5 and 20 Ibuprofen Oral 800 mg Unchanged NA 
Rofecoxib Oral 25 mg Unchanged NA 
Medow et al20 Skin 5 Ketorolac Local (microdialysis) 10 mM* 75% increase 150% increase 
Percent increase or decrease presented as rounded approximations for legibility. 
*Dmg concentration in rnicrodialysis ftuid. 
AUC, area under curve; NA, not available. 
reach peak plasma level after a single oral dose, as shown in 
detail in pharmacokinetic data of healthy volunteers. 30 In 
these studies, furthermore, the concentrations obtained after 
intake of a 30-mg tablet remained for at least 6 hours above 
400 µ,g/L ( ""==' 1 nM), a concentration shown to effectively 
block the vasoconstriction induced by U46619, a TP receptor 
agonist, in an ex vivo model.32 In addition, 2 studies showed 
the ability of a single oral dose of 10 mg S 18886 to improve 
ftow-mediated vasodilation when evaluated 2 hours after drug 
intake in patients with high cardiovascular risk and evidence of 
endothelial dysfunction.33•34 Taken together, these data make 
it very unlikely that our negative results could be explained by 
insufficient tissue concentration of the TP receptor antagonist. 
If efficient tissue concentrations of Sl8886 were reached 
in our conditions, the negative results imply either that vaso-
constrictor prostanoids did not in fact modulate the observed 
postischemic responses or that they did via pathways distinct 
from TP receptor signaling. The first possibility would run 
counter to the evidence, cited in the Introduction, that ischemia 
as shmt as carried out here markedly increases the production of 
TxA2 in human forearm. However, this evidence cornes from 
mostly ancient studies having assessed thromboxane B2 (the 
stable metabolite of TxA2) with immunoassays26-29 and whose 
results could not be replicated with more specific methods based 
on gas chromatography-tandem mass spectrometry.35 lt remains 
that the previously mentioned marked augmentation of reactive 
hyperemia by the local blockade of COX (using microdialysis 
for drug administration)2° is a strong argument in favor of a mod-
ulatory influence of vasoconstrictor prostanoids, at least in the 
skin. Such influence could be exe1ted by eicosanoids distinct 
from TxA2, able to stimulate non-TP receptors that would be 
insensitive to S 18886. The family of prostanoid receptors 
comprises multiple members, 13 of which not only the TP 
but also the EPl,36 EP3,37 and FP38 types are able to mediate 
the contraction of vascular smooth muscle. Further work 
would be required to determine whether reactive hyperemia 
in human forearm tissue is modulated by eicosanoid ligands 
to these additional receptors, such as prostaglandin E2 (EPl 
and EP3) or prostaglandin F2a (FP). 13 
© 2013 Lippincott Williams & Wilkins 
CONCLUSIONS 
Blockade of the TP receptor with S 18886 did not affect 
the reactive hyperemia elicited by a sho1t period of ischemia 
in the forearm muscle and skin ofyoung healthy male humans. 
Because the importance of vasoconstrictive prostanoids increases 
with aging, 39 it remains to be determined whether a similar 
conclusion holds in older subjects. Fmther studies are anyway 
required to detennine the pathways whereby COX products 
modulate postischemic vasodilation. 
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